A cell-based study published in Nature Communications on July 31, 2026 reports that a short, species-divergent stretch of the huntingtin gene, the proline-rich domain at the end of exon 1, helps determine how much of the toxic HTT1a transcript a cell makes. Working with an engineered mouse embryonic stem cell platform called HuntEx1, in which each line carries a different HTT exon 1 allele on an otherwise identical genetic background, the group led by Camilla Maffezzini, Raffaele Iennaco and Andrea Scolz, with Gillian P. Bates and Elena Cattaneo among the senior authors, found that the human proline-rich domain promotes HTT1a production, and that replacing it with the mouse equivalent inside an otherwise human exon 1 markedly reduced HTT1a levels. The paper is an accelerated preview, peer reviewed but not yet in its final edited form.
The direction of the mechanism is the opposite of what a quick reading might suggest. Motif analysis identified binding sites for Serine-Arginine Splicing Factor 7 (SRSF7) in the mouse proline-rich domain but not the human one, and SRSF7 appears to suppress HTT1a, most likely by pushing the cell to complete the normal splice from exon 1 to exon 2. The authors tested this by mutating the relevant CACCAC motif in mouse sequence and by introducing a comparable motif into human sequence in newly generated stem cell lines. They also report that the domain shapes the local structure of the messenger RNA, and they flag a further putative SRSF7 site in the human N17 region that they did not resolve.
Why this matters for families and for laboratories is model choice. HTT1a is the short, incompletely spliced transcript first described by Kirupa Sathasivam and colleagues in the Proceedings of the National Academy of Sciences in 2013, generated in proportion to CAG repeat length and translated into the exon 1 huntingtin protein fragment that aggregates readily and is widely considered an early driver of Huntington's disease. If human sequence context, and not the CAG repeat alone, sets how much of that fragment is made, then mouse models built on mouse flanking sequence may under-report the very species researchers are trying to study.
The counterpoint is that none of this was done in people or in brain tissue. The experiments are in engineered mouse stem cells carrying defined exon 1 alleles; there are no behavioural, neuronal loss or clinical outcomes, and no demonstration that altering SRSF7 binding changes disease course in any animal, let alone a person. SRSF7 is a general splicing factor with many targets across the genome, so it is not a ready drug target. Splicing-modulating drugs are already in Huntington's trials, including votoplam in the phase 2 PIVOT-HD study, but those agents were designed to lower full-length huntingtin; work by Sandra Fienko and colleagues in Brain in 2022 cautioned that approaches aimed at full-length HTT alone would not be expected to reduce the exon 1 protein.